ArticleJournal of inflammation research2025
Downregulation of IL-20RA in Cerebrospinal Fluid Associated with the Risk of Moyamoya Disease: A Molecular Signatures Analysis with an Inflammation Proteomics Landscape.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Moyamoya disease (MMD) is a cerebrovascular disorder with diverse clinical manifestations. Surgical revascularization is currently the optimal choice in the treatment of MMD; however, it could not prevent the progression of the disease. Inflammation and immunity factors have been reported to play the pivotal role in the pathogenesis of MMD, but there were still limited studies concerning the inflammatory landscape. Here, we aimed to investigate the molecular signatures of MMD to outline the inflammatory feature of MMD. Patients and Methods: A total of 89 MMD patients and 93 healthy subjects were recruited for this study. We then divided all patients into screening cohort (15 MMD patients and 21 healthy subjects) and validation cohort (74 MMD patients and 72 healthy subjects). Proteomic analysis of the cerebrospinal fluid (CSF) was performed in the screening cohort, which contained 363 inflammation-related molecules. Then we used ELISA assay to validation of molecules of differential expression. Results: We screened 192 inflammation-related proteins that were differentially expressed in the CSF of MMD patients. Among that, 191 proteins were upregulated, while IL-20RA were downregulated (p=0.042). The bioinformatic analysis found a potential inflammatory landscape of MMD, offering clues for pathogenetic and therapeutic targets in the mechanistic study. We then validated that downregulation of IL-20RA in CSF was associated with the risk of MMD in the validation cohort. Conclusion: This study provided molecular signatures of MMD with a large-scale proteomic analysis of CSF. IL-20RA might be a key element in the pathogenesis of MMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.